<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00871910</url>
  </required_header>
  <id_info>
    <org_study_id>P04630</org_study_id>
    <nct_id>NCT00871910</nct_id>
  </id_info>
  <brief_title>Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)</brief_title>
  <official_title>A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Cyclin-Dependent Kinase (CDK) Inhibitor SCH 727965 Administered Every 3 Weeks in Subjects With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part 1 and Part 2 of this trial will evaluate the safety, tolerability, maximum administered
      dose, and dose limiting toxicity of SCH 727965 administered every 3 weeks as a 2 hour
      intravenous (IV) infusion (Part 1), and as an 8-hour or 24-hour IV infusion (Part 2). Each
      3-week period is considered one treatment cycle. Part 3 of this trial will evaluate the
      effect of coadministration of antiemetic drug aprepitant on the pharmacokinetics of SCH
      727965 administered as a 2 hour IV infusion once every 3 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 11, 2006</start_date>
  <completion_date type="Actual">February 22, 2010</completion_date>
  <primary_completion_date type="Actual">February 22, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of SCH 727965, including maximum administered dose and dose-limiting toxicity</measure>
    <time_frame>End of trial</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>In Part 1 and Part 2, pharmacodynamic effects of SCH 727965 with an ex vivo lymphocyte stimulation assay of participant's peripheral blood lymphocytes.</measure>
    <time_frame>Cycle 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In Part 3, area under the plasma concentration versus time curve and maximum concentration of SCH 727965 administered as a 2 hour intravenous infusion with or without aprepitant in participants with advanced malignancies.</measure>
    <time_frame>Cycle 1 Days 1 and 2, and Cycle 2 Days 1 and 2</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>2 Hour SCH 727965 infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants treated with 2 hour SCH 727965 IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8 Hour SCH 727965 infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants treated with 8 hour SCH 727965 IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24 Hour SCH 727965 infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants treated with 24 hour SCH 727965 IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Hour SCH 727965 infusions plus aprepitant in Cycle 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to 2 Hour SCH 727965 infusion, plus concomitant ondansetron and dexamethasone in Cycles 1 and 2, and aprepitant in Cycle 1 only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Hour SCH 727965 infusion plus aprepitant in Cycle 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to 2 Hour SCH 727965 infusion, plus concomitant ondansetron and dexamethasone in Cycles 1 and 2, and aprepitant in Cycle 2 only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 727965</intervention_name>
    <description>SCH 727965 2 hour IV infusion on Day 1 of each 3 week cycle, administered in dose-escalating cohorts (Part 1 of the trial)</description>
    <arm_group_label>2 Hour SCH 727965 infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 727965</intervention_name>
    <description>SCH 727965 8 hour IV infusion on Day 1 of each 3 week cycle,in dose-escalating cohorts</description>
    <arm_group_label>8 Hour SCH 727965 infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 727965</intervention_name>
    <description>SCH 727965 24 hour IV infusion on Day 1 of each 3 week cycle, in dose-escalating cohorts</description>
    <arm_group_label>24 Hour SCH 727965 infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 727965</intervention_name>
    <description>SCH 727965 29.6 mg/m2 2 hour IV infusion on Day 1 of each 3 week cycle</description>
    <arm_group_label>2 Hour SCH 727965 infusions plus aprepitant in Cycle 1</arm_group_label>
    <arm_group_label>2 Hour SCH 727965 infusion plus aprepitant in Cycle 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <description>Oral aprepitant in Cycle 1 or Cycle 2, depending on the study arm: 125 mg 1 hour prior to the SCH 727965 infusion on Day 1, and 80 mg on Days 2 and 3.</description>
    <arm_group_label>2 Hour SCH 727965 infusions plus aprepitant in Cycle 1</arm_group_label>
    <arm_group_label>2 Hour SCH 727965 infusion plus aprepitant in Cycle 2</arm_group_label>
    <other_name>Emend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Ondansetron 32 mg IV 30 minutes prior to the SCH 727965 infusion on Day 1 of Cycles 1 and 2.</description>
    <arm_group_label>2 Hour SCH 727965 infusions plus aprepitant in Cycle 1</arm_group_label>
    <arm_group_label>2 Hour SCH 727965 infusion plus aprepitant in Cycle 2</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Oral dexamethasone in Cycles 1 and 2: 12 mg 30 minutes prior to the SCH 727965 infusion on Day 1, and 8 mg in the morning on Days 2, 3, and 4.</description>
    <arm_group_label>2 Hour SCH 727965 infusions plus aprepitant in Cycle 1</arm_group_label>
    <arm_group_label>2 Hour SCH 727965 infusion plus aprepitant in Cycle 2</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;=18 years, either sex, any race.

          -  Subjects must have histologically proven solid tumors, non-Hodgkin's lymphoma, or
             multiple myeloma.

          -  There must be no known standard therapy, or disease must be refractory to standard
             therapy.

          -  Eastern Cooperative Oncology Group performance status of 0, 1, or 2.

          -  Adequate hematologic, renal, and hepatic organ function and laboratory parameters.

        Exclusion Criteria:

          -  Symptomatic brain metastases or primary central nervous system malignancy.

          -  Previous radiation therapy to &gt;25% of the total bone marrow.

          -  Previous treatment with SCH 727965.

          -  Known HIV infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Zhang D, Mita M, Shapiro GI, Poon J, Small K, Tzontcheva A, Kantesaria B, Zhu Y, Bannerji R, Statkevich P. Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies. Cancer Chemother Pharmacol. 2012 Dec;70(6):891-8. doi: 10.1007/s00280-012-1967-y. Epub 2012 Oct 9.</citation>
    <PMID>23053255</PMID>
  </results_reference>
  <results_reference>
    <citation>Mita MM, Mita AC, Moseley JL, Poon J, Small KA, Jou YM, Kirschmeier P, Zhang D, Zhu Y, Statkevich P, Sankhala KK, Sarantopoulos J, Cleary JM, Chirieac LR, Rodig SJ, Bannerji R, Shapiro GI. Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies. Br J Cancer. 2017 Oct 24;117(9):1258-1268. doi: 10.1038/bjc.2017.288. Epub 2017 Aug 31.</citation>
    <PMID>28859059</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>March 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2009</study_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

